RAD51B Antibody

What is RAD51B and why is it important in research?

RAD51B is a key protein in the RAD51 family involved in DNA repair processes, particularly homologous recombination. It plays a crucial role in maintaining genomic stability by helping repair DNA double-strand breaks. RAD51B forms complexes with other RAD51 paralogs, including RAD51C, RAD51D, and XRCC2, which are essential for accurate DNA repair . The importance of RAD51B extends to human disease, as dysregulation has been linked to cancer development where impaired DNA repair mechanisms can contribute to tumor progression . Additionally, polymorphisms in the RAD51B gene have been associated with rheumatoid arthritis susceptibility in multiple populations, including European, Korean, and Han Chinese populations . Research into RAD51B is therefore vital for understanding both fundamental DNA repair mechanisms and disease pathogenesis.

What types of RAD51B antibodies are available for research?

Researchers have access to several types of RAD51B antibodies, which can be categorized based on their production method and host species:

• Polyclonal antibodies: These are typically produced in rabbits against recombinant RAD51B proteins. For example, the RAD51B Polyclonal Antibody (CAB6962) is raised against a recombinant fusion protein corresponding to amino acids 1-384 of human RAD51B .

• Monoclonal antibodies: These offer higher specificity and consistency between batches. The RAD51B Antibody (1H3/13) is a mouse monoclonal IgG2a kappa antibody raised against a His-tagged recombinant full-length human RAD51B protein .

Antibodies are available in various formats including:

• Unconjugated forms for standard applications

• Conjugated forms (with agarose, HRP, PE, FITC, or Alexa Fluor® dyes) for specialized detection methods

When selecting an antibody, researchers should consider the specific application, host species compatibility, and the particular domain of RAD51B being targeted.

What are the common applications for RAD51B antibodies?

RAD51B antibodies have multiple research applications, each requiring specific optimization:

When optimizing these applications, researchers should consider that RAD51B forms complexes with other proteins, particularly RAD51C. This interaction has been confirmed through co-immunoprecipitation studies where anti-RAD51B antibodies precipitated not only RAD51B but also RAD51C . This knowledge is especially important when designing experiments to study RAD51B's role in protein complexes involved in DNA repair.

How should I validate a RAD51B antibody before use?

Proper validation of RAD51B antibodies is crucial for generating reliable research data:

• Positive and negative controls: Include known positive samples (e.g., mouse or rat kidney extracts have been validated as positive samples for certain RAD51B antibodies) . For negative controls, consider using RAD51B-knockdown cells or tissues from RAD51B-knockout models if available.

• Western blot validation: Confirm the antibody detects a single band at the expected molecular weight of approximately 40 kDa for RAD51B . Multiple bands may indicate non-specific binding.

• Immunofluorescence pattern verification: RAD51B typically shows nuclear localization, particularly after DNA damage. Verify this pattern in your experimental system.

• Cross-reactivity assessment: Check the antibody's reactivity with related RAD51 family members. Some antibodies are highly specific to RAD51B, while others may cross-react with paralogs.

• Literature comparison: Compare your results with published findings using the same or similar antibodies to confirm expected patterns of expression or localization.

When validating new lots of antibodies, researchers should perform side-by-side comparisons with previously validated lots to ensure consistency in experimental outcomes.

How can RAD51B antibodies be used to study homologous recombination efficiency?

RAD51B antibodies provide valuable tools for investigating homologous recombination (HR) efficiency through several advanced approaches:

• RAD51 foci formation assays: RAD51B silencing has been shown to significantly impair RAD51 nuclear foci formation following DNA damage . Researchers can use RAD51B antibodies in combination with RAD51 antibodies to assess how RAD51B affects this critical process. This approach has effectively predicted clinical responses to homologous recombination deficiency (HRD)-targeting therapies, including PARP inhibition .

• Chromatin immunoprecipitation (ChIP): RAD51B antibodies can be used in ChIP assays to determine RAD51B recruitment to DNA damage sites, providing insight into HR initiation and progression.

• Proximity ligation assays (PLA): These can be used with RAD51B antibodies to detect interactions with other DNA repair proteins in situ, revealing the spatial and temporal dynamics of repair complex formation.

• Immunofluorescence co-localization studies: By combining RAD51B antibodies with antibodies against other DNA repair factors, researchers can assess the recruitment and retention of RAD51B at sites of DNA damage.

The experimental evidence shows that RAD51B has a mediator function in promoting RAD51 filament formation, which is essential for homologous pairing and strand exchange . This recombination mediator function of RAD51B-RAD51C is likely required for the assembly of the RAD51-ssDNA nucleoprotein filament in vivo , making antibody-based detection of these processes invaluable for understanding HR mechanics.

What methodologies can detect the RAD51B-RAD51C complex formation?

The stable association between RAD51B and RAD51C can be detected through several methodological approaches:

• Co-immunoprecipitation (Co-IP): This is the gold standard approach demonstrated in published research. Anti-RAD51B antibodies have been shown to precipitate not only RAD51B but also RAD51C, and similarly, anti-RAD51C antibodies co-precipitate RAD51B . For optimal results:

  • Use gentle lysis buffers to preserve protein-protein interactions

  • Include protease and phosphatase inhibitors

  • Consider chemical crosslinking to stabilize transient interactions

• Size exclusion chromatography: Research has shown that RAD51B and RAD51C co-elute precisely from Q Sepharose columns (fractions 8-16 in published studies) , suggesting they form a complex of specific size and charge properties.

• Bimolecular fluorescence complementation (BiFC): By tagging RAD51B and RAD51C with complementary fragments of a fluorescent protein, their interaction can be visualized in living cells.

• FRET (Förster Resonance Energy Transfer): Using fluorescently labeled antibodies against RAD51B and RAD51C, researchers can detect their close proximity, indicative of complex formation.

• Mass spectrometry following immunoprecipitation: This can identify not only the presence of the complex but also additional interacting partners and potential post-translational modifications.

These techniques are particularly important because the RAD51B-RAD51C complex serves a mediator function in Rad51/RecA family protein-mediated homologous recombination, facilitating the assembly of the Rad51-ssDNA nucleoprotein filament in vivo .

How can RAD51B antibodies contribute to cancer research?

RAD51B antibodies offer valuable approaches for investigating the role of this protein in cancer development, progression, and treatment response:

• Biomarker development: Germline loss-of-function variants in RAD51B have been associated with breast and ovarian cancer susceptibility (odds ratio for breast and ovarian cancer susceptibility of 2.69) . RAD51B antibodies can help assess protein expression levels in patient samples, potentially serving as biomarkers for cancer risk or treatment response.

• Homologous recombination deficiency (HRD) assessment: By examining RAD51B expression and localization using specific antibodies, researchers can identify potential HRD in tumors, which may predict sensitivity to PARP inhibitors and platinum-based chemotherapies.

• Functional assays for variant classification: For identified RAD51B variants, antibodies can help determine if protein expression, stability, localization, or function is affected, aiding in classifying variants as pathogenic or benign.

• Therapeutic target identification: Understanding RAD51B's role in DNA repair through antibody-based studies may reveal vulnerabilities in cancer cells that can be exploited therapeutically.

• Resistance mechanism studies: Changes in RAD51B expression or function may contribute to therapy resistance, which can be monitored using antibodies in pre- and post-treatment samples.

Research has demonstrated that silencing of RAD51B significantly impairs RAD51 nuclear foci formation following DNA damage , suggesting that RAD51B loss-of-function may contribute to genomic instability in cancer. This finding supports the inclusion of RAD51B in clinical germline testing panels for breast and ovarian cancer susceptibility .

What role does RAD51B play in rheumatoid arthritis and how can antibodies help study this?

RAD51B has been implicated in rheumatoid arthritis (RA) pathogenesis through genome-wide association studies, and antibodies offer several approaches to investigate this connection:

• Genotype-phenotype correlation studies: RAD51B antibodies can be used to examine protein expression levels in relation to specific gene variants, particularly the SNP rs911263, which has been consistently identified as significantly associated with RA susceptibility in multiple populations .

• Mechanism exploration: While RAD51B primarily functions in DNA repair, its association with autoimmune conditions like RA suggests alternative functions. Antibodies can help track RAD51B in immune cells and tissues to uncover these mechanisms.

• Disease severity correlation: Research has shown that the rs911263 SNP in RAD51B is not only associated with RA susceptibility but also with erosion, a clinical assessment of disease severity (P = 2.89 × 10⁻⁵, OR = 0.52) . Antibodies can help quantify RAD51B levels in relation to disease progression.

Key findings from research across different populations include:

The protective effect of the variant allele appears stronger in the Han Chinese population (OR = 0.5-0.6) compared to European populations (OR ≈ 0.8) , highlighting the importance of studying RAD51B across different ethnic groups. Antibody-based techniques can help determine if these genetic differences translate to functional variations in protein expression or activity.

Why might I observe inconsistent RAD51B detection in Western blots?

Inconsistent RAD51B detection in Western blots can stem from several methodological issues:

• Sample preparation challenges:

  • RAD51B is primarily nuclear and may require specialized nuclear extraction protocols

  • Protein degradation during extraction can be prevented by using fresh protease inhibitors

  • Cross-contamination between nuclear and cytoplasmic fractions may affect results

• Technical considerations:

  • Insufficient blocking can lead to high background

  • Inappropriate antibody dilution (optimal range typically 1:500 - 1:2000 for RAD51B antibodies)

  • Transfer efficiency issues, particularly for proteins around 40 kDa like RAD51B

• Biological factors:

  • Cell-cycle dependent expression of RAD51B

  • Variation in expression levels across different cell types or tissues

  • Post-translational modifications affecting antibody recognition

• Antibody-specific issues:

  • Lot-to-lot variation, particularly with polyclonal antibodies

  • Storage conditions affecting antibody quality

  • Cross-reactivity with other RAD51 family members

When troubleshooting, researchers should include appropriate positive controls, such as mouse or rat kidney extracts, which have been validated as positive samples for certain RAD51B antibodies . Additionally, comparing results with published literature showing the expected ~40 kDa band size can help confirm proper detection . For applications requiring high consistency, monoclonal antibodies like the RAD51B Antibody (1H3/13) may provide more reliable results than polyclonal alternatives .

How can I optimize immunofluorescence detection of RAD51B?

Optimizing immunofluorescence (IF) detection of RAD51B requires attention to several key parameters:

• Fixation method optimization:

  • Paraformaldehyde (4%) is commonly used but may mask some epitopes

  • Methanol fixation can better preserve nuclear proteins like RAD51B

  • Test multiple fixation methods to determine optimal epitope accessibility

• Permeabilization considerations:

  • Nuclear proteins require effective permeabilization

  • Triton X-100 (0.1-0.5%) is typically effective for RAD51B detection

  • Excessive permeabilization can disrupt nuclear architecture and affect results

• Antibody dilution and incubation:

  • Start with manufacturer's recommended range (typically 1:200 - 1:800)

  • Longer incubation at 4°C (overnight) often provides better signal-to-noise ratio

  • Consider using antibody diluents containing BSA or serum to reduce background

• Signal amplification strategies:

  • Conjugated secondary antibodies (with bright fluorophores)

  • Tyramide signal amplification for weak signals

  • Using pre-conjugated primary antibodies (if available)

• Controls and validation:

  • Include positive controls (cell lines known to express RAD51B)

  • Negative controls (primary antibody omission, RAD51B-knockdown cells)

  • Co-staining with antibodies against known interacting partners (e.g., RAD51C)

For studying DNA damage responses, inducing DNA damage with agents like ionizing radiation or hydroxyurea can increase RAD51B recruitment to damage sites, making detection more prominent. The expected pattern is nuclear localization, often appearing as discrete foci following DNA damage, reflecting RAD51B's role in homologous recombination repair .

What are common pitfalls in co-immunoprecipitation experiments with RAD51B?

Co-immunoprecipitation (Co-IP) of RAD51B with its interacting partners requires careful consideration of several potential pitfalls:

• Complex stability challenges:

  • The RAD51B-RAD51C complex may be disrupted by harsh lysis conditions

  • Use gentle lysis buffers (e.g., those containing 0.1% NP-40 or Triton X-100)

  • Consider chemical crosslinking to stabilize transient interactions

• Antibody selection issues:

  • Some antibodies may recognize epitopes involved in protein-protein interactions

  • Epitope masking can occur when RAD51B is bound to partners like RAD51C

  • Test multiple antibodies targeting different regions of RAD51B

• Non-specific binding problems:

  • High background due to insufficient washing

  • Non-specific binding to beads or IgG

  • Use pre-clearing steps with beads alone before adding specific antibodies

• Elution challenges:

  • Incomplete elution of complexes from beads

  • Harsh elution conditions denaturing interaction partners

  • Consider native elution with competing peptides for certain applications

• Control considerations:

  • Always include IgG control from the same species as the primary antibody

  • Input controls (5-10% of lysate used for IP) should be run alongside IP samples

  • Reciprocal IPs (using antibodies against interaction partners) strengthen findings

Based on published research, successful co-immunoprecipitation of the RAD51B-RAD51C complex has been achieved, demonstrating their stable association . In these experiments, anti-RAD51B antibodies precipitated not only RAD51B but also RAD51C, and similarly, anti-RAD51C antibodies co-precipitated RAD51B . This reciprocal validation approach strengthens confidence in the detected interaction.

How should I interpret varying RAD51B expression levels across different cell types?

Interpreting variation in RAD51B expression across different cell types requires consideration of several biological and technical factors:

• Biological factors affecting expression:

  • Cell cycle stage: RAD51B expression may vary throughout the cell cycle, with potential upregulation during S and G2 phases when homologous recombination is most active

  • Tissue-specific regulation: Different tissues may have varying baseline expression levels

  • Differentiation state: Stem cells versus differentiated cells may show different expression patterns

  • Stress response: DNA damage may induce RAD51B expression or relocalization

• Quantification approaches:

  • Western blotting with proper loading controls (e.g., GAPDH, β-actin)

  • Quantitative immunofluorescence with nuclear counterstaining

  • RT-qPCR to assess mRNA levels in parallel with protein detection

  • Flow cytometry for high-throughput single-cell analysis

• Normalization considerations:

  • For cell lines with different nuclear-to-cytoplasmic ratios, nuclear protein normalization may be more appropriate than whole-cell protein

  • Consider normalizing to other DNA repair proteins to assess relative expression

  • In tissues, cell-type-specific markers can help interpret heterogeneous expression

• Functional correlation:

  • Higher RAD51B expression may correlate with increased homologous recombination efficiency

  • In cancer cells, altered expression may indicate potential therapeutic vulnerabilities

  • Expression patterns should be interpreted in the context of other RAD51 paralogs

Published research provides some baseline expectations: RAD51B is endogenously expressed in human HeLa cells at detectable levels , and mouse and rat kidney samples have been validated as positive controls for certain RAD51B antibodies . When interpreting results from different cell types, researchers should consider both absolute expression levels and the ratio of RAD51B to other DNA repair proteins, particularly its complex partner RAD51C.

How does RAD51B expression correlate with cancer susceptibility and progression?

The relationship between RAD51B expression and cancer involves complex interactions between germline variants, somatic mutations, and altered protein function:

• Germline variant implications:

  • Loss-of-function germline variants in RAD51B have been associated with increased susceptibility to breast and ovarian cancers with an odds ratio of 2.69 (95% CI: 1.4–5.3)

  • These findings suggest RAD51B should be considered for inclusion in clinical germline testing panels for cancer susceptibility

  • Researchers should consider sequencing RAD51B alongside expression analysis to identify potential pathogenic variants

• Expression patterns in tumors:

  • Both overexpression and underexpression of RAD51B have been observed in different cancer types

  • Reduced expression may lead to homologous recombination deficiency, increasing genomic instability

  • Increased expression might represent a compensatory mechanism in response to genomic instability

• Functional implications in cancer cells:

  • Silencing of RAD51B results in significantly impaired RAD51 nuclear foci formation following DNA damage

  • This deficiency in homologous recombination repair may contribute to cancer development and progression

  • It may also predict sensitivity to specific therapies like PARP inhibitors

• Therapeutic relevance:

  • Tumors with RAD51B deficiency may show synthetic lethality with PARP inhibitors

  • RAD51B status may serve as a biomarker for treatment selection

  • Monitoring RAD51B expression before and after treatment may help track therapy resistance

When analyzing cancer samples, researchers should consider that RAD51B function depends not only on expression levels but also on proper complex formation with RAD51C and other interacting partners . Therefore, comprehensive analysis should include co-expression studies and functional assays measuring homologous recombination efficiency.

What is the significance of RAD51B polymorphisms in rheumatoid arthritis?

The association between RAD51B polymorphisms and rheumatoid arthritis (RA) represents an intriguing connection between DNA repair genes and autoimmune disease:

• Consistent genetic associations:

  • The SNP rs911263 in RAD51B has been repeatedly identified as significantly associated with RA susceptibility across multiple populations

  • In European populations, rs911263 showed genome-wide significant association with anti-CCP-positive RA (P = 4 × 10⁻⁸, OR = 0.89)

  • In Han Chinese populations, the same SNP showed strong association (P = 4.8 × 10⁻⁵, OR = 0.64)

• Disease severity correlation:

  • Beyond mere susceptibility, rs911263 has been linked to erosion, a clinical marker of RA severity (P = 2.89 × 10⁻⁵, OR = 0.52)

  • This suggests RAD51B's influence extends beyond disease initiation to progression and severity

• Population differences:

  • The protective effect appears stronger in Han Chinese (OR = 0.5-0.6) compared to European populations (OR ≈ 0.8)

  • This highlights the importance of studying RAD51B across different ethnic backgrounds

• Mechanistic hypotheses:

  • The functional link between RAD51B and RA remains unclear, but several possibilities exist:

    • Altered DNA repair in immune cells may affect apoptosis or inflammatory responses

    • RAD51B polymorphisms might be in linkage disequilibrium with other functional variants

    • RAD51B may have unknown functions beyond DNA repair that influence immune regulation

• Research approaches:

  • Antibody-based studies comparing RAD51B expression and localization in immune cells from RA patients versus controls

  • Functional assays measuring DNA repair efficiency in cells with different RAD51B genotypes

  • Analysis of RAD51B expression in synovial tissues from RA patients

While RAD51B's primary known function is in DNA repair through homologous recombination , its consistent association with RA suggests either pleiotropic effects or undiscovered functions relevant to autoimmunity. Further research using RAD51B antibodies could help elucidate these connections and potentially identify new therapeutic targets.

How can RAD51B antibodies help identify homologous recombination deficiency?

RAD51B antibodies provide valuable tools for identifying homologous recombination deficiency (HRD), which has significant implications for cancer diagnosis and treatment:

• Functional assays for HRD detection:

  • RAD51 foci formation assay: Silencing of RAD51B has been shown to significantly impair RAD51 nuclear foci formation following DNA damage

  • This assay requires antibodies against both RAD51B (to confirm knockdown) and RAD51 (to assess foci formation)

  • The accumulation of RAD51 nuclear foci in response to DNA damage reflects the fidelity of upstream components of the HR pathway and predicts responses to HRD-targeting therapies

• Complex formation assessment:

  • RAD51B forms a complex with RAD51C that acts as a mediator in Rad51/RecA family protein-mediated homologous recombination

  • Antibodies can be used to assess both the expression and interaction of these proteins

  • Disruption of complex formation may indicate functional HRD even when protein expression appears normal

• Clinical implications:

  • HRD tumors may be sensitive to PARP inhibitors and platinum-based chemotherapies

  • RAD51B status assessment could help guide treatment decisions

  • Germline RAD51B variants confer susceptibility to breast and ovarian cancers , suggesting screening value

• Methodological approaches:

  • Immunohistochemistry on tumor samples to assess RAD51B expression

  • Immunofluorescence for RAD51 foci quantification after DNA damage induction

  • Co-immunoprecipitation to detect RAD51B-RAD51C complex formation

  • Western blotting to measure total protein levels

When implementing these assays, researchers should consider that HRD can result from defects in various HR pathway components. Therefore, comprehensive assessment should include multiple markers beyond RAD51B alone. Additionally, functional assays (like RAD51 foci formation) often provide more clinically relevant information than simple expression analysis.

What new technologies are enhancing RAD51B antibody applications?

Recent technological advances have expanded the capabilities of RAD51B antibody-based research:

• Super-resolution microscopy techniques:

  • Structured illumination microscopy (SIM), stimulated emission depletion (STED), and photoactivated localization microscopy (PALM) provide nanoscale resolution

  • These techniques allow visualization of RAD51B within DNA repair foci at unprecedented detail

  • Combined with specific antibodies, these approaches reveal spatial organization of repair complexes

• Proximity labeling methods:

  • BioID and APEX2 proximity labeling coupled with RAD51B antibodies for immunoprecipitation

  • These techniques identify proteins in close proximity to RAD51B in living cells

  • Particularly valuable for discovering new interaction partners beyond known complexes with RAD51C

• Single-cell analysis platforms:

  • Mass cytometry (CyTOF) using metal-conjugated RAD51B antibodies

  • Single-cell Western blotting for heterogeneity analysis

  • These approaches reveal cell-to-cell variation in RAD51B expression and localization

• Antibody engineering advances:

  • Recombinant antibody production improving lot-to-lot consistency

  • Fragment antibodies (Fabs) for applications requiring smaller probes

  • Bi-specific antibodies for simultaneous detection of RAD51B and interacting partners

• Microfluidic immunoassays:

  • Automated, high-throughput platforms for quantitative analysis

  • Reduced sample requirements compared to traditional Western blotting

  • Potential for clinical translation in cancer diagnostics

These technological advances enable researchers to move beyond traditional applications like Western blotting and basic immunofluorescence. For instance, the availability of recombinant antibodies like the Rad51 (F1G6C) Rabbit mAb provides superior lot-to-lot consistency, continuous supply, and animal-free manufacturing , addressing key limitations of traditional antibody production. These improvements are particularly valuable for longitudinal studies and clinical applications where reproducibility is essential.

How are computational approaches enhancing RAD51B antibody research?

Computational methods are increasingly integrated with antibody-based experimental approaches to advance RAD51B research:

• Image analysis automation:

  • Machine learning algorithms for automated quantification of RAD51B foci

  • Convolutional neural networks can distinguish true foci from background noise

  • High-throughput analysis enables screening of factors affecting RAD51B localization

• Structural biology integration:

  • Computational modeling of RAD51B-antibody interactions helps predict epitope accessibility

  • Molecular dynamics simulations reveal conformational changes affecting antibody binding

  • Structure-guided epitope selection for antibody development targeting specific functional domains

• Multi-omics data integration:

  • Correlation of RAD51B protein levels (from antibody-based detection) with transcriptomics data

  • Integration with genomics data on RAD51B variants (like rs911263) associated with diseases

  • Network analysis to position RAD51B within broader DNA repair and disease pathways

• Biomarker development pipelines:

  • Statistical approaches for validating RAD51B as a biomarker for cancer susceptibility

  • Machine learning models incorporating RAD51B with other markers for improved prediction

  • Survival analysis correlating RAD51B expression with clinical outcomes

• In silico epitope mapping and antibody design:

  • Computational prediction of immunogenic epitopes for antibody development

  • Virtual screening to optimize antibody binding characteristics

  • Design of peptide-specific antibodies targeting particular RAD51B domains

These computational approaches enhance traditional antibody applications by improving data quality, increasing analysis throughput, and connecting protein-level findings to broader biological contexts. For instance, when investigating the relationship between RAD51B polymorphisms and rheumatoid arthritis, computational approaches can help determine whether observed associations (like the SNP rs911263 with OR = 0.64) reflect direct functional effects or linkage to other causal variants.

What emerging roles of RAD51B beyond DNA repair can be studied with antibodies?

While RAD51B is primarily known for its role in homologous recombination DNA repair, emerging research suggests additional functions that can be investigated using antibody-based approaches:

• Potential immune system roles:

  • The consistent association of RAD51B polymorphisms with rheumatoid arthritis suggests possible immune-related functions

  • Antibodies can help track RAD51B expression in immune cell populations

  • Immunoprecipitation followed by mass spectrometry might reveal immune-specific interaction partners

• Transcriptional regulation:

  • Several DNA repair proteins have secondary roles in transcription regulation

  • Chromatin immunoprecipitation using RAD51B antibodies can identify potential DNA binding sites outside damage contexts

  • Co-immunoprecipitation may reveal interactions with transcription factors

• Cell cycle control mechanisms:

  • RAD51B may have functions in cell cycle checkpoint regulation

  • Antibody-based cell synchronization studies can reveal cell cycle-dependent localization

  • Phospho-specific antibodies might detect cell cycle-dependent modifications

• RNA metabolism connections:

  • Some DNA repair proteins interact with RNA or RNA-binding proteins

  • RNA immunoprecipitation using RAD51B antibodies could identify RNA interactions

  • Immunofluorescence co-localization with RNA processing factors might reveal novel functions

• Mitochondrial DNA maintenance:

  • Nuclear DNA repair proteins sometimes have mitochondrial roles

  • Fractionation studies with RAD51B antibodies can determine mitochondrial localization

  • Super-resolution microscopy can visualize potential mitochondrial functions

The association of RAD51B with diseases beyond cancer, particularly rheumatoid arthritis, is intriguing. The SNP rs911263 in RAD51B has been identified as significantly associated with RA susceptibility in multiple studies , and its effect appears stronger in Han Chinese populations (OR = 0.5-0.6) compared to European populations (OR ≈ 0.8) . This consistent disease association across populations suggests functions beyond the well-established DNA repair role, which could be elucidated through innovative antibody-based approaches.